Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 19.3%

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) was the recipient of a significant growth in short interest in February. As of February 13th, there was short interest totaling 10,541,776 shares, a growth of 19.3% from the January 29th total of 8,839,652 shares. Currently, 15.1% of the shares of the stock are short sold. Based on an average trading volume of 845,002 shares, the days-to-cover ratio is presently 12.5 days. Based on an average trading volume of 845,002 shares, the days-to-cover ratio is presently 12.5 days. Currently, 15.1% of the shares of the stock are short sold.

Inhibikase Therapeutics Price Performance

IKT stock opened at $1.89 on Friday. The stock has a 50 day moving average price of $1.78. The stock has a market cap of $142.09 million, a PE ratio of -4.85 and a beta of 0.76. Inhibikase Therapeutics has a one year low of $1.33 and a one year high of $2.58.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on IKT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, January 22nd. HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday, December 26th. Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a research note on Thursday, December 11th. Zacks Research upgraded Inhibikase Therapeutics to a “hold” rating in a report on Tuesday, December 2nd. Finally, LADENBURG THALM/SH SH upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research report on Wednesday. Four analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy”.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.